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The Journal of Immunology
A Tumor Mitochondria Vaccine Protects against
Experimental Renal Cell Carcinoma
Stefano Pierini,*,†,1 Chongyun Fang,*,1 Stavros Rafail,*,1 John G. Facciponte,*
Jialing Huang,* Francesco De Sanctis,*,‡ Mark A. Morgan,* Mireia Uribe-Herranz,*
Janos L. Tanyi,* and Andrea Facciabene*
Mitochondria provide energy for cells via oxidative phosphorylation. Reactive oxygen species, a byproduct of this mitochondrial
respiration, can damage mitochondrial DNA (mtDNA), and somatic mtDNA mutations have been found in all colorectal, ovarian,
breast, urinary bladder, kidney, lung, and pancreatic tumors studied. The resulting altered mitochondrial proteins or tumor-
associated mitochondrial Ags (TAMAs) are potentially immunogenic, suggesting that they may be targetable Ags for cancer
immunotherapy. In this article, we show that the RENCA tumor cell line harbors TAMAs that can drive an antitumor immune
response.We generated a cellular tumor vaccine by pulsing dendritic cells with enriched mitochondrial proteins fromRENCA cells.
Our dendritic cell–based RENCA mitochondrial lysate vaccine elicited a cytotoxic T cell response in vivo and conferred durable
protection against challenge with RENCA cells when used in a prophylactic or therapeutic setting. By sequencing mtDNA from
RENCA cells, we identified two mutated molecules: COX1 and ND5. Peptide vaccines generated from mitochondrial-encoded
COX1 but not from ND5 had therapeutic properties similar to RENCA mitochondrial protein preparation. Thus, TAMAs can
elicit effective antitumor immune responses, potentially providing a new immunotherapeutic strategy to treat cancer. The
Journal of Immunology, 2015, 195: 4020–4027.
R
ecent research advances in cancer immunotherapy have
progressed rapidly, culminating in durable remission for
hematological malignancies using T cells that express
a chimeric AgR (CAR) targeted against CD19 (1). Manipulation of
immune responses as cancer therapy is very different compared with
direct pharmacological attack on the tumor, so it is not surprising that
immunotherapy is still generating unexpected and often conflicting
results, as well as occasional adverse events (2). Breakthroughs in
therapeutically targeting solid malignancies remain elusive, and the
identification of novel tumor associated Ags (TAAs) continues to be
a critically important requirement. In this article, we describe tumor
mitochondria-derived peptides as a source of novel TAAs.
The typical human cell contains ∼100 mitochondria, each of
which has an average of five mitochondrial DNA (mtDNA) mol-
ecules, yielding ∼500 copies of mtDNA/cell (3). Interestingly,
mtDNA lacks repair proteins and protective histones found in
nuclear DNA and, at the same time, reactive oxygen species
(ROS) produced by oxidative phosphorylation (4) result in muta-
tions that are more abundant in mtDNA than in nuclear DNA (5,
6). During physiological development, mtDNA mutations exist
in a heteroplasmic state: within a single cell, some mitochondrial
genomes harbor mutations, whereas others do not. In contrast,
human tumors have a high frequency of homoplasmic mtDNA.
This observation has been interpreted as reflecting a growth ad-
vantage or other advantage for tumor cells containing certain
homoplasmic mtDNA mutations (5, 7).
Mitochondrial Ags are presented to and recognized by the
immune system, and there is evidence that mitochondrial peptides
may participate in the induction of autoimmune diseases (8, 9). For
example, autoreactive T cell responses to peptides derived from
the pyruvate dehydrogenase complex are found in almost all cir-
rhosis patients (10). Antimitochondrial immune responses also
occur in cancer, as illustrated by the presence of CD4+ T cells
specific for cytochrome B among tumor-infiltrating lymphocytes
isolated and expanded from melanoma biopsies (11). Somatic
mtDNA mutations are present in up to 100% of kidney, colorectal,
ovarian, breast, urinary bladder, lung, and pancreas tumors (12,
13). These features suggest that the mitochondria may be a source
of novel tumor-associated mitochondrial Ags (TAMAs) that could
be used to develop therapeutic vaccines to treat cancer.
In this article, we describe a vaccine strategy that uses dendritic
cells (DCs) pulsed with mitochondrial lysate, including TAMAs
isolated from tumor cells. We selected murine kidney tumor cells as
the model system because previous studies characterized renal cell
carcinoma as being highly sensitive to immunotherapy (14–16) and
having a high incidence of mtDNA mutations (17, 18). We gen-
erated the DC-based vaccine using mitochondria-enriched lysate
from RENCA cells, a spontaneously arising renal adenocarcinoma
(19, 20), and vaccinated mice both prophylactically and thera-
peutically. Protective immunity was observed when the TAMA
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vaccine was used prophylactically; it also was effective in delaying
tumor growth in the therapeutic setting. We sequenced and aligned
the 13 coding sequences included in the mtDNA from RENCA cells
or kidneys of BALB/c mice (which are syngeneic with RENCA cells)
and identified two TAMA candidates within the sequences of the
mitochondrial-encoded COX1 and ND5 genes of the RENCA cells.
To confirm that the T cell response against these TAMAs generated
effective immunity, we immunized mice with peptides derived from
these mutated genes. The resulting immune responses impaired
RENCA tumor growth in a CD8+ T cell–specific manner. We con-
clude that targeting TAMAs is a novel immunotherapy approach that
is effective, safe, and has durable responses.
Materials and Methods
Mice and cell lines
BALB/c (H-2d) mice (8-wk-old) were purchased from The Jackson Lab-
oratory. Murine renal carcinoma RENCA and colon carcinoma line CT26
(H-2d) were purchased from the American Type Culture Collection.
Purification of mitochondria and mtDNA extraction
Mitochondria were purified from RENCA cell lines and tissues (RENCA
solid tumor and kidney) using the discontinuous sucrose gradient method
described previously (21). Preparations were frozen (liquid nitrogen) and
thawed (37˚C, water bath) for three cycles, sonicated, and irradiated at
5000 rad for sterilization. Quantification was carried out with the BCA
assay. mtDNA was isolated from cell lines using a Mitochondrial DNA
Isolation Kit from BIOVISION.
Tumor lysate preparation
Cultured RENCA cells were detached from tissue flasks with trypsin and
washed twice with PBS. Cells were resuspended in PBS, frozen/thawed six
times, and quantified by BCA assay.
Western blot
Western blot was performed with mitochondrial extract proteins with Abs
specific for COX4 (clone 1D6E1A8), GAPDH (clone 71.1), or histone H3
(Sigma; polyclonal). Membranes were incubated with a 1:3000 dilution of
HRP-conjugated Abs and developed with the ECL system.
Mouse bone marrow–derived DC generation and maturation
Bone marrow cells were isolated from hind leg femurs and tibias of mice,
and DCs were isolated, cultured, and matured as previously described (22).
DC uptake
Intact mitochondria and live tumor cells were stained for 10 min at 37˚C in
0.5 mM CellTrace CFSE. Stained preparations were divided into aliquots
that were frozen/thawed. Frozen/thawed CFSE cells and frozen/thawed
CFSE mitochondria were cocultured with normal DCs (100 mg/ml) for 3
and 6 h at 37˚C. DC uptake was evaluated using flow cytometry with
a FACSCanto. For microscopic analysis, immature DCs and CFSE-stained
mitochondria were cocultured for 4 h, cytocentrifuged, fixed in 4% para-
formaldehyde, and mounted with DAPI Fluoromount-G. Slides were ex-
amined using a confocal microscope (Leica). Adherent cells at the bottom
of the plate after coculture were washed in PBS, fixed, and mounted with
DAPI Fluoromount-G. DC uptake was monitored using a fluorescence
microscope (ECLIPSE Ti; Nikon).
Synthetic peptides and peptide immunization
Mutated COX1291–306 (MFTVGLDVDTRTYFT), COX1295–310
(GLDVDTRTYFTSATM), and COX1299–314 (DTRTYFTSATMIIAI)
peptides were purchased from Eunoia Biotech. Mutated ND5516–535
(SFSTLLGFFTSIIHR), ND5520–539 (LLGFFTSIIHRITPM), and ND5524–543
(FTSIIHRITPMKSLN) peptides were purchased from Mimotopes (23). For
prophylactic peptide vaccination, mice were divided into different groups
and immunized three times with 100 mg of either the combination of the
three mutated COX1 peptides or the combination of the three mutated ND5
peptides; each individual peptide was distributed in an equimolar manner
in the multipeptide preparations. The vaccination consisted of three injec-
tions at weekly intervals in CFA and IFA. One week after the last immu-
nization, animals were challenged with a s.c. injection of 1 3 105 RENCA
cells and monitored for tumor growth every other day.
DC-based immunotherapy
Mitochondria from RENCA solid tumors and RENCA cell lines, as well as
control mitochondria, were purified, cocultured with BALB/c-derived DCs,
and matured as described above. In prophylactic settings, DC vaccine
pulsed with 100 mg/ml protein lysate/million cells was administered in-
tradermally (13 106 DCs/dose in 100 ml PBS) once weekly for 3 wk. Two
weeks after the last injection, mice were inoculated s.c. with 1 3 106 live
RENCA cells. In the therapeutic protocol, mice were injected s.c. with 13
106 RENCA cells and, starting 1 wk later, they were given three injections
of 1 3 106 DCs at weekly intervals. Tumor progression was monitored
every other day from the tumor challenge.
Adoptive cell transfer
Tumor-free BALB/c mice were vaccinated three times with mitochondria-
pulsed DCs or control DCs and sacrificed 1 wk later. CD3+, CD4+, and
CD8+ T cells were magnetically isolated from the spleens, and serum was
collected by intracardiac bleeding. Isolated T cells were injected i.v. into
RENCA tumor–bearing mice (challenged 7 d before transfer) that had
been sublethally irradiated (4–5 Gy) 8 d before adoptive transfer. Serum
was administered i.p. twice weekly for a total of six injections into
RENCA tumor–bearing mice.
Immunohistochemistry
CD3+ cells were detected by immunohistochemistry in solid tumors.
Tumors were embedded in OCT and immediately snap-frozen in dry ice.
Sections (6 mm thick) were stained for CD3, as previously described (24).
Slides were analyzed in a blinded fashion by two independent observers.
ELISPOT for IFN-g
Isolated CD3+ T cells from the spleen of tumor-bearing mice were
cocultured for 16 h with RENCA cells at a 10:1 ratio. After incubation,
plates were washed with PBS and Tween 20, ELISPOT was performed,
and spots were counted using an automated ELISPOT reader (Autoimmun
Diagnostika) (24).
Cytokine analysis and flow cytometry
In a 24-well plate, 13 106 immature DCs were exposed to mitochondria or
whole-tumor lysate (100 ng/ml) in DC complete media for 12 h. Cocul-
tures were matured overnight with LPS (1 mg/ml) and IFN-g (100 ng/ml).
Cells were harvested, and supernatant was collected and analyzed for IL-2,
IL-5, and MCP-1 by the Human Immunology Core, University of Penn-
sylvania. Cells were labeled with mAbs from eBioscience (CD11b [clone
M1/70], CD11c [clone N418], PD-L1 [clone MIH5]), BD Biosciences
(CD86 [clone GL1], CD80 [clone 16-10A1]), and BioLegend (CD40
[clone 3/23], CD45 [clone 30-F11]). Labeled cells were evaluated with a
FACSCanto, and the data were analyzed using FlowJo software (TreeStar).
DCs were gated as CD11b+/CD11c+.
Intracellular cytokine staining for IFN-g
A total of 1–3 3 106 mouse splenocytes was incubated with the indicated
peptides (final concentration of each peptide, 10 mg/ml) and 1 mg/ml Golgi
Stop (BD Biosciences, Pharmingen) at 37˚C for 12–16 h and labeled with
CD3+/CD4+ or CD8+ and IFN-g, as previously described (25). Cells were
analyzed on a FACSCanto flow cytometer using FlowJo software.
Urine total protein and creatinine quantification
Urine and serum from mice that received three doses of DC-based vaccine
(DC alone, DC pulsed with RENCA-derived mitochondria [DC/RENCA
mito], and DC pulsed with healthy kidney mitochondria [DC/Kidney
mito]), as well as from control animals, were collected and assessed for
total protein and creatinine levels. Samples were analyzed by the core
service at the Ryan Veterinary Hospital at the University of Pennsylvania.
Histological evaluation of kidney in vaccinated mice
Kidneys of DC-vaccinated mice were collected to assess for possible
treatment toxicity. Tissues were fixed in 10% buffered formalin and em-
bedded in paraffin. Histopathologic evaluation was performed on standard
H&E-stained sections. Microscopic analysis was performed separately and
in a blinded fashion by two independent observers.
mtDNA amplification and sequencing
Protein-coding sequences were amplified using PCR with 22 pairs of
overlapping primers (Supplemental Table I). PCRs were carried out in
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25-ml reactions using Phusion DNA polymerase (New England Biolabs)
and 10 ng mtDNA template. Prior to sequencing, PCR products were
cleaned up using a PureLink Quick PCR Purification Kit (Invitrogen; Life
Technologies), and DNA concentration was determined by NanoDrop.
Sanger Sequencing was performed on an ABI 3770 (Applied Biosystems)
at the Penn Genomics Analysis Core of the University of Pennsylvania.
Sequencing was performed with the same primers used for PCR.
Data analysis
For CD3+ T cell quantification in tumor sections and ELISPOT, statistical
analyses for the indicated comparisons were performed using the pairwise
Student t test. All p values presented are two sided. The log-rank test was
performed for the survival curves. Single-step multiple-comparison pro-
cedure Tukey test was performed for repeated measurements at different
time points. All experiments were performed a minimum of three times; in
the case of in vivo studies, each group consisted of 10 animals, unless
otherwise noted. All figures portray one representative experiment.
Study approval
All animal studies were approved by the Institutional Animal Care and Use
Committee and University Laboratory Animal Resources at the University
of Pennsylvania. Mice were treated in accordance with University of
Pennsylvania guidelines.
Results
Mitochondria enriched from tumor cells are taken up by DCs
but do not induce maturation
For all experiments, mitochondria were prepared from tissues or
cell culture by dounce homogenization, low-speed centrifugation
to remove nuclei, and high-speed centrifugation to enrich for
mitochondria. Functional mitochondria were isolated using a dis-
continuous density sucrose gradient. Enrichment was confirmed by
Western blot (Fig. 1A) using specific Abs for mitochondria protein
(26) (COX4; top row), the cytosolic compartment protein (27)
(GAPDH; middle row), and nuclei (histone H3; bottom row).
Danger-associated molecular pattern mediators, such as
mtDNA, ATP, and formylated peptides, which are released during
apoptosis or necrosis, enhance the inflammatory response (28, 29).
Because DCs also express receptors for mtDNA (30), we inves-
tigated the response of bone marrow–derived DCs (bmDCs) from
BALB/c mice. bmDCs were cultured in GM-CSF and IL-4 and
then exposed to RENCA lysate enriched for mitochondria,
RENCA whole-cell lysate, or LPS plus IFN-g for 12 h (31). Mi-
tochondria lysate did not induce any significant upregulation of
the maturation markers CD80, CD86, CD40, or PD-L1 (Fig. 1B).
Activated DCs secrete Th1 or Th2 and other polarizing cytokines
(32); therefore, bmDCs were pulsed with mitochondrial lysate or
cell lysate, and supernatants were analyzed for IL-2 (33), IL-5
(34), and MCP1. We measured a modest increase in IL-2 and
IL-5 that did not reach statistical significance (Fig. 1C) and con-
cluded that mitochondrial lysate does not activate bmDCs in vitro.
One hallmark of Ag presentation is the active engulfment of
extracellular material (35). To demonstrate that mitochondria ly-
sate was engulfed by bmDCs, freshly isolated intact mitochondria
were labeled with CFSE, centrifuged, and frozen/thawed to
rupture the mitochondria. When the CFSE-labeled mitochondria
lysate was fed to immature bmDCs, both the cell lysate and
mitochondrial lysate were actively engulfed by immature DCs
(Fig. 1D).
DC/RENCA mito lysate suppress tumor growth and induce
long-term protection
To examine the effects of mitochondria-based DC vaccines on
renal tumor growth, we initially performed prophylactic immu-
nizations. BALB/c mice were immunized intradermally with
BALB/c-derived bmDCs pulsed with mitochondrial lysate derived
from RENCA tumors extracted from tumor-bearing mice, from
RENCA cells grown in vitro, or from kidneys from healthy mice.
FIGURE 1. Mitochondria lysate is engulfed by in vitro–derived bmDCs but does not induce maturation. (A) Mitochondrial enrichment of tumor lysate
was verified by Western blot analysis using mitochondria-specific COX4, cytosolic GAPDH, and nuclei-specific histone H3 Abs. (B) Immature DCs were
pulsed with mitochondrial preparation (Mito) or whole-tumor lysate (WTL) and then matured with IFN-g and LPS (right panels) or left untreated (left
panels). CD11c, CD11b double-positive cells were analyzed for CD40, CD80, CD86, and PD-L1 markers by flow cytometry. (C) Cytokine production
(IL-2, IL-5, and MCP1) was measured from supernatants of immature DCs cocultured with mitochondria (DC + mito) or immature unpulsed DCs (DC)
(p = not significant between pulsed and unpulsed samples for all cytokines examined, all data pg/ml). (D) DCs are able to engulf mitochondria. Mito-
chondria and live tumor cells were stained with CFSE. CFSE-stained preparations were cocultured with immature DCs for 3 and 6 h (upper left panel and
upper right panel, respectively) and analyzed by flow cytometry. Fluorescence microscopy (lower left panel) and confocal microscopy (lower right panel)
revealed DCs (blue nuclei) and CFSE mitochondria (green)-overlapping pixels, indicating active uptake of mitochondria by immature DCs.
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Immunization was performed weekly for a total of three immuni-
zations. Mice immunized with DCs pulsed with RENCA tumor–
derived mitochondria (DC/Solid Tumor mito) rejected 80% of
tumors, whereas the animals immunized with in vitro–cultured DC/
RENCA mito rejected 70% of tumors, indicating that these lysates
induce protective immune responses. Mitochondria enriched from
normal kidney did not elicit a highly protective response (Fig. 2A).
Adaptive immunotherapy can generate long-lasting memory that
protects the host against tumor persistence or recurrence (36, 37).
Mice that rejected tumor after the first challenge were rechal-
lenged with RENCA cells 3 mo later. All of the animals previ-
ously immunized with DC/RENCA mito were protected against
the second tumor challenge. The few surviving animals from the
group that had been immunized with DC/Kidney mito (Fig. 2B,
d) were rechallenged with RENCA and succumbed after 10 d
(p , 0.05, log-rank test).
DC/RENCA mito lysate protect mice when used
therapeutically, promote T cell infiltration of tumors, and
induce IFN-g production by T cells
We first challenged mice with RENCA tumor cells, followed by
injection of bmDCs pulsed with mitochondrial lysate derived from
RENCA cells grown in vitro or from healthy kidney cells. DCs
alone or pulsed with healthy kidney mitochondria had no thera-
peutic effect, whereas DC/RENCA mito significantly delayed
tumor development (Fig. 3A, Supplemental Fig. 2) (p , 0.01).
CD3+ infiltration into the tumors of mice treated with DC/RENCA
mito was observed, whereas DC/Kidney mito proteins or DCs
alone did not elicit significant CD3+ cell infiltration (Fig. 3C) (p,
0.0001, DC/RENCA mito versus DC/Kidney mito, t test). We next
tested the capacity of T cells purified from animals that had been
immunized with DCs to recognize RENCA cells in vitro, using
IFN-g secretion as an indication of recognition. Purified T cells
derived from DC/RENCA mito–immunized animals vigorously
responded to RENCA cells in vitro, whereas T cells from DC/
Kidney mito–immunized animals did not respond (Fig. 3B) (p ,
0.00001, DC/RENCA mito versus DC/Kidney mito, t test). CT26
cells used as a tumor cell line control did not elicit significant
IFN-g by T cells derived from DC/RENCA mito–immunized
animals, demonstrating the specificity of the T cell response
(Fig. 3B).
RENCA mitochondria vaccine drives a T cell–specific immune
response against tumors
To determine whether the antitumor response by mitochondria-
enriched RENCA vaccine is cellular or humoral in nature, we
performed adoptive transfer of total CD3+ T cells, CD4+ T cells,
CD8+ T cells, or serum from mitochondria-enriched immunized
FIGURE 2. Prophylactic vaccination using DCs loaded with RENCA
mitochondria lysate suppresses tumor growth and induces long-term pro-
tection. (A) BALB/c lysate derived from RENCA solid tumors (DC/Solid
Tumor mito) resected from 20-d-old tumor-bearing mice, from RENCA
cells grown in vitro (DC/RENCA mito), or from kidneys (DC/Kidney
mito) of healthy mice. Two weeks after the last immunization, animals
were injected (s.c.) with 1 3 106 RENCA cells and monitored for tumor
growth. Data are mean (n = 10 mice/group for each experiment). p , 0.05,
Tumor mito or RENCA mito versus Kidney mito, log-rank test. (B) Ani-
mals that rejected tumors after the first challenge in (A) were rechallenged
with RENCA cells 3 mo later. All of the animals previously immunized
with DC/RENCA mito and DC/Solid Tumor mito were protected after
a second challenge.
FIGURE 3. Therapeutic vaccination with DCs loaded
with RENCA mitochondria lysate controls tumor pro-
gression. (A) In a therapeutic setting, mice were chal-
lenged s.c. with 1 3 106 RENCA cells and were
vaccinated 1 wk later with bmDCs pulsed with DC/
RENCA mito, DC/Kidney mito, or DCs alone (DC).
Data are mean 6 SEM (n = 10 mice/group for each
experiment, except DC group [n = 5]). All p values are
pairwise multiple comparisons. p , 0.01, DC/RENCA
mito versus DC/Kidney mito or versus DCs, Tukey test.
(B) T cells isolated from DC/RENCA mito–vaccinated
mice are reactive against RENCA cells. Purified T cells
(1 3 105) from DC/RENCA mito–vaccinated mice
were cocultured with stimulator RENCA cells or con-
trol CT26 cells (10:1 ratio), and IFN-g ELISPOT was
performed. (C) Immunohistochemistry (left panels) was
performed, which quantitatively demonstrated heavy
CD3+ cell infiltration into RENCA tumors of animals
treated with DC/RENCA mito (right panel). Original
magnification 320.
The Journal of Immunology 4023
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mice into lymphodepleted (irradiated) RENCA tumor–bearing
mice. Serum and CD3+ cells from nonimmunized mice were in-
cluded as additional controls (24). Fig. 4 demonstrates that the
antitumor response generated by the DC/RENCA mito vaccine
was mediated by T cells (Fig. 4A), whereas serum (Fig. 4B)
lacked any therapeutic effect. The cell-transfer experiments also
illustrate the central role played by CD8+ T cells in comparison
with CD4+ T cells, because adoptive transfer of CD8+ or total
CD3+ T cells results in complete rejection of tumors. As shown in
Fig. 2, heavy T cell infiltration was observed in each of the groups
adoptively transferred with CD3+ and CD8+ cells, whereas mini-
mal CD3+ T cell infiltration was observed in mice that were
adoptively transferred with CD3+ T cells from naive (nonimmu-
nized) mice.
Sequencing of the 13 coding sequences included in the mtDNA
of RENCA cells reveals two TAMA candidates
mtDNA is tens to hundreds times more likely to acquire mutations
compared with nuclear DNA. Mechanisms that facilitate mtDNA
mutations include the generation of ROS in close proximity to the
mtDNA, the lack of histones, less extensive repair mechanisms
than nuclear DNA, and a nucleotide imbalance that leads to de-
creased polymerase g fidelity (4, 6). Given that some components
of the mitochondrial lysate from RENCA contained the TAMAs,
we chose to sequence the 13 coding sequences of mtDNA. mtDNA
was purified from several RENCA cell lines and amplified by
PCR with 22 pairs of overlapping primers (Supplemental Table I).
Two point mutations generating amino acid alterations were
FIGURE 4. Adoptive transfer demonstrates a T cell–mediated antitumor
effect upon vaccination using DCs loaded with RENCA mitochondria
lysate. Tumor-free mice (BALB/c) were vaccinated with DCs pulsed with
RENCA mitochondria lysate as previously described; mice were sacrificed
1 wk after the last vaccination, and lymphocyte populations (CD3+, CD4+,
and CD8+ T cells) were isolated from splenocytes. Serum was also col-
lected from vaccinated and naive mice (nonimmunized). (A) Isolated CD3+,
CD4+, and CD8+ T cells and naive CD3+ T cells were injected i.v. into
RENCA tumor–bearing mice (challenged 1 wk before the adoptive trans-
fer) that were sublethally irradiated (4–5 Gy) 8 d before adoptive transfer.
Data are mean 6 SEM (n = 10 mice/group for each experiment). Adop-
tively transferred CD3+, CD4+, or CD8+ T cells control tumor progression
and result in CD3+ T cell infiltration. p , 0.0001, CD8 and CD3 versus
naive CD3; p, 0.001, CD4 versus naive CD3. (B) Serum, injected i.p. into
another group of mice, did not control tumor progression (p = not significant).
FIGURE 5. Screening of RENCA mtDNA reveals a mutation in COX1 protein that generates a neo-“nonself” epitope. mtDNA was amplified by PCR
with 22 pairs of overlapping primers. (A) RENCA COX1 alignment to the reference sequence (EF108333.1, Mus musculus strain BALB/cByJ mito-
chondrion, complete genome) revealed the mutation G6234A; the enlarged chromatogram shows the probable homoplasmic nature of the mutation (COX1-
II F6 and R6 PCR primers; Supplemental Table I). (B) Mutated COX1291–306 peptide reacts to DC/RENCA mito–immunized CD8
+ T cells. Three COX1
peptides were generated and used for overnight in vitro restimulation of splenocytes obtained from DC/RENCA mito–immunized mice. Specific CD3+/
CD8+ T cell reactivity against COX1291–306, but not against the other COX1 peptides or ND5 mutated control peptides (Supplemental Fig. 1B), was
measured for IFN-g by intracellular cytokine staining. (C) Multipeptide COX1 immunization results in RENCA tumor growth control. A minimum of five
mice/group was immunized with the mutated COX1 peptide pools, mutated ND5 peptide pools, or control preparation. One week later, mice were injected
s.c. with 13 105 RENCA cells, and tumor progression was monitored, showing a protection of COX1-immunized animals. p = 0.021, versus control group,
or p = 0.036, two-tailed ANOVA). (D) At the end point of the experiment, splenocytes of these mice were isolated and tested in vitro for reactivity against
the mutated COX1 peptides by IFN-g ELISPOT assay. p , 0.05, peptide 291–306 versus 295–310 or 299–314.
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identified: one mutation was in position G6234A, which converted
Ala to Thr in COX1 cytochrome oxidase I (complex IV) (Fig. 5A),
and the other was in position C13330A (Pro to Thr) in the ND5
subunit of NADH (protein complex I) (Supplemental Fig. 1A).
To verify the functional relevance of the identified TAMA
candidates, we designed peptides for vaccination or for in vitro
restimulation and included these mutations (38). For each TAMA,
three peptides were generated, each 15 aa in length and over-
lapping by 5 aa, including the mutation (39). These peptides were
used for overnight in vitro restimulation of splenocytes obtained
from RENCA mitochondria protein lysate–pulsed DC-immunized
mice. Splenocytes (CD8+ T cells) from mice immunized with
DC/RENCA mito specifically recognized the first mutated
COX1291–306 peptide (MFTVGLDVDTRTYFT) (Fig. 5B) but not
any of the ND5-mutated peptides (Supplemental Fig. 1B). Mice
were then immunized with the COX1291–306 peptide in CFA and
then boosted twice with the same peptide in IFA, followed by
RENCA challenge. In agreement with the IFN-g results, the COX1-
mutated peptides induced a significant decrease in tumor burden,
whereas ND5-mutated peptides also attenuated tumor growth,
but it did not reach statistical significance (Fig. 5C). Splenocytes
(CD8+) from COX1 peptide–immunized animals responded to the
first COX1291–306 mutant peptide but not control, confirming the
inclusion of the immune dominant epitope of the TAMA within
the COX1291–306 peptide (Fig. 5D, Supplemental Fig. 1C).
RENCA-derived mitochondrial vaccine does not affect kidney
functions
To evaluate whether our treatment had an impact on renal func-
tion, we collected urine and serum from treated and control animals
and tested them for total protein and creatinine, a metabolic waste
product that is removed from the blood chiefly by the kidneys. If
kidney filtration is deficient, creatinine blood levels rise accord-
ingly. Because serum proteins are readily reabsorbed from urine,
the presence of excess protein indicates either an insufficiency of
absorption or impaired filtration (40). We found no indication of
toxicity or dysfunction in the mice receiving DC vaccines against
RENCA targets, confirming the safety of our approach (Fig. 6A,
6B). Finally, because the vaccines target kidney tumor cells via
T cell–mediated immune responses, we examined the kidneys of
treated and untreated animals (control) by H&E and CD3+ stain-
ing, with a pathologist blindly scoring the slides. No gross dif-
ferences between the groups were identified, demonstrating that
there are no off-target effects (Fig. 6C).
Discussion
DCs, the professional APCs of the immune system, can be
exploited for cancer immunotherapy (41). DCs activate effector
mechanisms, including Ag-specific cytotoxic T lymphocytes, Abs,
and NK cells, and generate long-lasting immune memory (42).
Preclinical and early clinical data confirm that DC vaccines induce
potent immune responses (43). Given that each patient may ex-
press his/her own set of TAMAs and a specific MHC haplotype,
the isolation of tumor mitochondria for the generation of a DC-
based vaccine represents an innovative approach to personalized
immunotherapy. Moreover, the use of mitochondria lysate pro-
vides the entire possible repertoire of full-length TAMAs in-
cluded in the specimen, bypassing the major limitation of epitope/
peptide-based cancer vaccines (i.e., MHC restriction). In this ar-
ticle, we present evidence that mitochondrial protein lysates are
taken up by DCs and presented to T cells, eliciting a CD8+ IFN-g+
T cell response specific for TAMAs. DC/RENCA mito lysate
protect mice in both a therapeutic and prophylactic setting. Pro-
phylactic vaccination of RENCA tumor–bearing mice using pep-
tides that included the COX1 mutation, but not the ND5 mutation,
conferred protection. Overall, our data suggest that mitochondria
from tumors provide a source of TAMAs that, in a model of renal
cancer, provide a safe and effective target for immunotherapy.
Renal cancer (as well as other cancer types) harbors multiple
mtDNA mutations and is particularly immunosensitive (16, 18,
44). In addition, immunotherapeutic strategies have an important
place in the management of advanced clear cell renal cell carci-
nomas (15, 16, 45). We used the well-established RENCA mouse
model and initiated our studies by purifying lysate for mito-
chondria and establishing that immature bmDCs could efficiently
engulf the lysate in vitro. Because mitochondrial danger-associated
FIGURE 6. Kidneys are unaffected by DC/RENCA
mito immunization. Urine and serum from vaccinated
mice (DC, DC/RENCA mito, and DC/Kidney mito)
and control animals (Normal) were collected and mea-
sured for total protein (A) and creatinine (B) levels. p =
not significant between normal versus any treatment in
either group. (C) Kidneys from vaccinated animals
were collected to assess for possible treatment toxicity.
Labeling of CD3+ T cells showed no differences in the
number of T cells infiltrating the kidneys of DC-
vaccinated animals (upper panels). H&E staining of
kidneys of DC-vaccinated mice showed no abnormal-
ities detected for either group (lower panels). Original
magnification 310.
The Journal of Immunology 4025
 at Bibl. M
eneghetti c/o D
EA
 on D
ecem
ber 10, 2016
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
molecular patterns released into the circulation during trauma
activate human peripheral polymorphonuclear neutrophils, leading
to degranulation, and DCs also express receptors for mitochon-
drial danger-associated molecular patterns (28, 29, 46), we hy-
pothesized that mitochondrial lysate would activate bmDCs;
however, we found that lysate did not activate or change the phe-
notype of IFN-g– or LPS-matured bmDCs. T cells isolated from
immunized mice actively secrete IFN-g in the presence of RENCA
target cells, whereas they do not respond to syngeneic CT26 colon
cancer cells, demonstrating the specificity of the immune response.
Tumor control of DC/RENCA mito vaccine is mediated pri-
marily by CD8+ T cells, whereas serum from vaccinated donors
did not play a therapeutic role in our adoptive-transfer experi-
ments. However, we did not directly measure anti-mitochondrial
Abs generated by our vaccine; therefore, we cannot entirely rule
out the possibility that mitochondrial vaccine–generated Abs con-
tribute to the observed efficacy of vaccine. Previous studies corre-
lated tumor progression and survival of cancer patients with the
number of tumor-infiltrating lymphocytes (47). In the mitochondria-
vaccinated mice there was marked T cell infiltration that was
specific to the DC/RENCA mito–immunized group; the control
group immunized with a vaccine prepared using healthy kidney
mitochondria showed no response.
Much of the ongoing efforts in the development of vaccines for
cancer and chronic infectious diseases is aimed at creating effec-
tive memory responses (48). Mice that were vaccinated with
DC/RENCA mito maintained their tumor-free status after being
rechallenged with RENCA tumors 3 mo later, illustrating the
effective generation of immune memory.
To identify the source of immunogenicity in the mitochondrial
lysate, we sequenced the 13 coding sequences of RENCA mtDNA.
This revealed two putative TAMAs within the COX1 and ND5
sequences. When we used mutated peptides from COX1 and ND5
for in vitro restimulation of splenocytes isolated from DC/RENCA
mito–vaccinated mice, only COX1 stimulation resulted in IFN-g
production. We then evaluated whether these peptides were di-
rectly involved in the mechanism of tumor rejection by using the
peptides as vaccines. The results confirmed our in vitro findings
because the COX1 peptide had prophylactic properties, whereas
the ND5 peptide did not. This finding indicates that TAMAs,
although not always immunogenic, can also serve as a source of
synthesized, peptide-based immunization strategies in our system.
The improvement in next-generation sequencing, as well as
other techniques, helped to underline the heterogeneity of tumor
nuclear mutations both within a single patient and across patients
(48). To account for tumor heterogeneity and mitochondrial homo-
plasmy in our study, we sequenced mitochondria from RENCA
cells of various passages and at different confluence levels. In our
model, the identified TAMAs were consistent between all of the
cell lines analyzed and the in vivo–derived cells (data not shown).
However, probably as a result of the heterogeneity in a given tu-
mor, a single type of immune therapy may only be effective in
a subpopulation of cancer patients; therefore, we claim that further
mitochondrial analysis is required to cover a greater repertoire of
cancer types at different stages. However, other immunotherapies
targeting specific TAAs (such as CAR T cell therapy and DC-
based vaccines) have been successful, despite the heterogeneity
of the tumors. This could be explained, in part, by mechanisms of
“cross-priming” induced by direct or indirect killing of tumor cells
expressing the target Ags and harboring other mutations.
Promising immunotherapy approaches, such as CAR T cell
therapy, DC therapy, and peptide vaccination, are only as effec-
tive as the selection of the TAA (49). Potential TAA candidates
must meet a number of criteria: they must be immunogenic,
abundantly expressed by tumor cells, not be expressed in normal
tissue to limit off-target effects, and functionally important for the
tumor, so that expression is unlikely to be lost. Several cancers’
histology harbor mutations in mtDNA and TAMAs that meet
most, if not all, of the criteria of an ideal TAA (11, 12). Lastly,
immunotherapies based on CAR depend on the specificity of the
TAA but often have toxic side effects, such as cytokine release
syndrome, which vary from patient to patient and can be fatal in
some cases (2, 50, 51). In addition, selection of a TAA for CAR
therapy requires the availability of high-affinity Abs (scFv), which
limits the pool of TAAs. Our data suggest that TAMAs may be
uniquely tumor specific; they do not generate off-target effects
and, when used with an effective immunotherapy platform, such
as DCs, can elicit tumor-specific T cell responses and durable
antitumor responses. To our knowledge, our study is the first to
demonstrate that tumor mtDNA mutations can be used to generate
a specific immune response upon active immunization in a murine
model of renal cancer, resulting in durable tumor rejection. Fur-
ther exploration and characterization of TAMAs may expand the
pool of suitable TAAs for inclusion in immunotherapy protocols
for different histological cancers.
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